Monday, August 2, 2021
News

Here's what you need to know about Oxford Covid-19 vaccine

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | Friday, 2021 7:15:06 PM IST
With the UK giving the green light to the Covid-19 vaccine developed by Oxford University and drug maker AstraZeneca, India is also expected to follow suit soon as a meeting of the decision-making body began on Friday, giving new hope of beginning the end of the pandemic as the New Year ushers in.

The authorisation in the UK recommended two doses administered with an interval of between four and 12 weeks.

This regimen was shown in clinical trials to be safe and effective at preventing symptomatic Covid-19, with no severe cases and no hospitalisations more than 14 days after the second dose, according to AstraZeneca.

Now known as Covid-19 Vaccine AstraZeneca, it was formerly called AZD1222.

AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

As announced on November 23, the primary efficacy endpoint based on a pooled analysis showed that the vaccine was 70.4 per cent effective at preventing symptomatic Covid-19 occurring more than 14 days after receiving two doses of the vaccine.

A secondary efficacy endpoint of prevention of severe disease demonstrated no cases of severe infections or hospitalisations in the vaccine group.

In addition to the programme led by Oxford University, AstraZeneca is conducting a large trial in the US and globally.

Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, is manufacturing a version of the Oxford-AstraZeneca Covid-19 vaccine "Covishield" in India.

Prime Minister Narendra Modi visited the Pune-based company on November 28 to review vaccine development.

The company this week said that it has a stockpile 40-50 million doses of its Covid-19 vaccine.

India is likely to receive majority of these 50 million doses.

"We have 40-50 million doses of Covishield stockpiled. Once we get regulatory approvals in a few days, it will be down to the government to decide how much they can take and how fast. We will be producing around 300 million doses by July 2021," Serum Institute CEO Adar Poonawalla recently said in a press conference.

The company applied for emergency authorisation of the vaccine in India in December.

It is expected that this vaccine will play a major role in India's plan to vaccinate its population against Covid-19 due to several factors including low-cost, ease of storage and transport.

--IANS gb/in

( 450 Words)

2021-01-01-13:12:06 (IANS)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Global spike in Covid cases may lead to ...
Lebanon registers 1,147 new Covid-19 cas...
Cambodia receives another batch of Sinop...
632 new Covid-19 cases reported in Fiji...
Vietnam reports 8,620 new Covid-19 cases...
New Covid cases outnumber recoveries in ...
More...
 
INDIA WORLD ASIA
Thunderstorm, rain likely in Delhi, Noid...
Shiv Sena slams BJP over 'demolish Shiv ...
Muslim man who looked after orphaned Hin...
BJP to launch rival event to Nitish Kuma...
KCR rewards Kaushik Reddy with MLC seat...
Assam CM directs police to withdraw FIR ...
More...    
 
 Top Stories
Rajasthan: BJP MP Kirodi Lal Meena ... 
Equity indices gain on strong globa... 
Microland recognized as 'Finalist' ... 
RS Floor leaders of like-minded Opp... 
Tokyo Olympics: Indian women's hock... 
Almost 300 stray dogs killed with p... 
Opposition maligning but world prai... 
Indian women's hockey team is scrip...